-

Theraclion: Monthly Information on the Total Number of Voting Rights and Shares Comprising the Share Capital

Article 223-16 du Règlement Général de l’Autorité des marchés financiers

MALAKOFF, France--(BUSINESS WIRE)--Regulatory News:

Theraclion (Paris:ALTHE):

Listed on Euronext Growth Paris
PEA PME eligible
ISIN Code : FR0010120402
Website : www.theraclion.com

Voting rights :

Date

Total number of shares of Theraclion

Total number of theoretical voting rights of Theraclion (1)

Total number of real voting rights of Theraclion (2)

31/05/2026

73 123 311

89 143 355

87 584 876

(1) Theoretical voting rights are calculated on the basis of all shares to which voting rights are attached, including shares stripped of voting rights, in accordance with Article 223-11 of the AMF's General Regulation
(2) Actual voting rights correspond to the total number of voting rights exercisable at the Annual General Meeting. They are calculated on the basis of the total number of voting rights attached to the total number of shares less shares stripped of voting rights.

About Theraclion

Theraclion is a French MedTech company developing a non-invasive alternative to surgery through the innovative use of focused ultrasound.
High-Intensity Focused Ultrasound (HIFU) does not require incisions or an operating room, leaves no scars, and allows patients to resume normal activities immediately. HIFU concentrates therapeutic ultrasound on an internal focal point from outside the body.
Theraclion is developing Sonovein®, a robotic HIFU platform for varicose vein treatment, CE marked under the MDR (EU 2017/745), with the potential to replace millions of surgical procedures each year. To date, Sonovein® has been adopted by more than a dozen centers worldwide and used in over 4,000 procedures. In the U.S., Sonovein® is not yet available for sale.
Based in Malakoff (Paris), Theraclion’s team comprises around 35 people.

For more information, please visit www.theraclion.com and follow the LinkedIn account.
Theraclion is listed on Euronext Growth Paris Eligible for the PEA-PME scheme
Ticker: ALTHE - ISIN Code: FR0010120402 LEI: 9695007X7HA7A1GCYD29

Contacts

Theraclion
Martin Deterre
Chief Executive Officer
investors@theraclion.com

Theraclion

BOURSE:ALTHE
Release Versions
EnglishFrench

Contacts

Theraclion
Martin Deterre
Chief Executive Officer
investors@theraclion.com

More News From Theraclion

Theraclion Obtains FDA Authorization for Sonovein®, Opening a New Era in Non-invasive Vein Care in the United States

MALAKOFF, France--(BUSINESS WIRE)--Regulatory News: THERACLION (ISIN: FR0010120402; Ticker: ALTHE), an innovative company developing Sonovein®, a platform for the non-invasive treatment of varicose veins using High-Intensity Focused Ultrasound (HIFU), today announces that the U.S. Food and Drug Administration (FDA) granted De Novo marketing authorization for Sonovein® on November 4, 2026. In the United States, Sonovein® is intended for the coagulation of blood vessels in patients with superfici...

Theraclion Strengthens Its Growth Prospects in the Middle East by Obtaining Marketing Authorisation for Sonovein® in Saudi Arabia

MALAKOFF, France--(BUSINESS WIRE)--Regulatory News: THERACLION (ISIN: FR0010120402; Ticker: ALTHE), an innovative company developing Sonovein®, a robotic platform for the non-invasive treatment of varicose veins using high-intensity focused ultrasound (HIFU), announces that it has obtained the Medical Device Marketing Authorization for Sonovein® from the regulatory authority of Saudi Arabia, the Saudi Food and Drug Authority (SFDA). It allows Theraclion to market the Sonovein® therapeutic ultra...

Theraclion Announces the Initiation of Coverage by TP ICAP Midcap With a Target Price of EUR 1.70, Confirming the Potential of Sonovein®

MALAKOFF, France--(BUSINESS WIRE)--Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing Sonovein®, a robotic platform for non-invasive varicose vein therapy using High-Intensity Focused Ultrasound (HIFU), announces today the initiation of coverage of its stock by TP ICAP Midcap, a brokerage firm and investment bank specialising in small and mid caps. In its initiation report published on 27 October 2026, TP ICAP Midcap initiated coverage of the stock...
Back to Newsroom